Table 1.
Clinical characteristics at diagnosis of AML patients divided according to miR-24 expression status
| miR-24 high expression | |||
|---|---|---|---|
|
|
|||
| + | - | P | |
| Sex (male/female) | 21/21 | 27/15 | 0.270 |
| Median age at diagnosis, years (range) | 53 (10-86) | 57 (15-87) | 0.164 |
| Median WBC at diagnosis, ×109 L-1 (range) | 8.4 (0.3-185.4) | 11.7 (1.1-528.0) | 0.697 |
| Median hemoglobin at diagnosis, g/L (range) | 75.0 (34.0-131.0) | 77.0 (40.0-138.0) | 0.333 |
| Median platelets at diagnosis, ×109 L-1 (range) | 33.0 (3.0-140.0) | 38.0 (4.0-264.0) | 0.707 |
| FAB | 0.053 | ||
| M1 | 2 | 4 | |
| M2 | 24 | 14 | |
| M3 | 6 | 11 | |
| M4 | 4 | 11 | |
| M5 | 5 | 2 | |
| WHO | 0.080 | ||
| AML with t(8;21) | 9 | 2 | |
| AML with t(15;17) | 6 | 11 | |
| AML without maturation | 2 | 4 | |
| AML with maturation | 15 | 12 | |
| Acute myelomonocytic leukemia | 5 | 11 | |
| Acute monoblastic and monocytic leukemia | 4 | 2 | |
| Karyotype classification | 0.919 | ||
| Favorable | 15 | 13 | |
| Intermediate | 23 | 23 | |
| Poor | 3 | 4 | |
| No date | 1 | 2 | |
| Karyotyping | 0.250 | ||
| Normal | 20 | 20 | |
| t(8;21) | 9 | 2 | |
| t(15;17) | 6 | 11 | |
| Complicated | 3 | 3 | |
| Others | 3 | 4 | |
| No date | 1 | 2 | |
| Gene mutation | |||
| NPM1 (+/-) | 5/37 | 4/37 | 1.000 |
| FLT3 ITD (+/-) | 6/36 | 6/35 | 1.000 |
| C-KIT (+/-) | 1/41 | 0/41 | 1.000 |
| IDH1/IDH2 (+/-) | 3/35 | 1/38 | 0.358 |
| DNMT3A (+/-) | 3/35 | 3/36 | 1.000 |
| NRAS/KRAS (+/-) | 4/34 | 3/36 | 0.711 |
| C/EBPA (+/-) | 6/36 | 3/38 | 0.483 |
| CR (+/-) | 23/18 | 20/19 | 0.823 |
| Median miR-24 expression (range) | 0.33 (0.13-3.31) | 0.01 (0.00-0.12) | < 0.001 |